EN
DE 
NL 
FR 
ES 
IT 
CS 
PL CONDITION
For MS muscle spasticity, a THC:CBD medicine is approved in many countries. Multiple sclerosis often causes painful muscle stiffness and spasms (spasticity). A balanced THC:CBD extract is approved in numerous countries to help, and the evidence is moderate and patient-reported.
What the research says
The National Academies 2017 report found substantial evidence that oral cannabinoids improve patient-reported multiple sclerosis spasticity, though evidence for clinician-measured spasticity was more limited. In practice, many patients report meaningful relief.
The approved medicine
Nabiximols (Sativex), a roughly 1:1 THC:CBD mouth spray, is approved in many countries (though not the US at time of writing) specifically for MS spasticity that has not responded to other treatments.
At a glance
What to be careful about
MS is a serious neurological condition managed by specialists. Cannabis-based medicine is an add-on for specific symptoms, not a replacement for disease-modifying treatment, and should be discussed with the treating team.
Continue exploring
Large-scale randomized clinical trials and evidence reviews in National Academies of Sciences, Engineering, and Medicine (NASEM, 2017, Bookshelf NBK425767), The Lancet (Zajicek et al., 2003, CAMS Trial, PMID 14615106), and European Journal of Neurology (Novotna et al., 2011, PMID 21362108) establish substantial evidence that oral and oromucosal cannabinoids improve patient-reported multiple sclerosis spasticity and central neuropathic pain. Standardized 1:1 THC:CBD formulations (nabiximols) pair CB1-mediated spinal motor inhibition with CBD buffering to reduce muscle spasms without severe intoxication.
Frequently Asked Questions
What did the 2017 NASEM review conclude about cannabis and multiple sclerosis?
The National Academies (NASEM 2017) found conclusive or substantial evidence that oral cannabinoids improve patient-reported multiple sclerosis spasticity symptoms, alongside limited evidence for clinician-measured Ashworth scale changes.
Why do prescription MS sprays use a 1:1 ratio of THC to CBD?
Nabiximols (Sativex) combines 2.7 mg Delta-9-THC with 2.5 mg CBD per spray so THC activates spinal CB1 receptors to dampen muscle spasticity while CBD moderates psychoactive side effects.
Do cannabinoids stop multiple sclerosis disease progression or relapses?
No. Clinical trials confirm that cannabinoids are used for symptomatic management of spasticity, nocturnal spasms, and neuropathic pain rather than modifying underlying autoimmune demyelination.
Sources & Clinical Trial References
- National Academies of Sciences, Engineering, and Medicine (2017). "Therapeutic Effects of Cannabis and Cannabinoids." In: The Health Effects of Cannabis and Cannabinoids. Washington (DC): National Academies Press. NCBI Bookshelf NBK425767.
- Zajicek, J., Fox, P., Sanders, H., et al. (2003). "Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial." The Lancet, 362(9395), 1517-1526. PubMed PMID 14615106.
- Novotna, A., Mares, J., Ratcliffe, S., et al. (2011). "A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis." European Journal of Neurology, 18(9), 1122-1131. PubMed PMID 21362108.
English